Abbvie (ABBV) PT Raised to $161 at BMO Capital Following Migraine Deep Dive
Tweet Send to a Friend
BMO Capital analyst Gary Nachman raised the price target on Abbvie (NYSE: ABBV) to $161.00 (from $154.00) while maintaining an ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
